6 of 100
6. Alexion Pharmaceuticals
3-year average
Revenue Growth: 75%
Profit Growth: 82%
Total Return: 37%
The company's first product to reach the market, Soliris-which treats a rare, but life-threatening disease that basically destroys red blood cells-has been a success. Sales rose about 50% in the most recent quarter compared to the equivalent period in 2010. Soliris is the only drug treating the blood disease, which is called paroxysmal nocturnal hemoglobinuria, and Alexion is now exploring other uses for its compound in the hopes of expanding the market for the medication.

Meanwhile, Alexion acquired Taligen Therapeutics early this year as part of its efforts to expand and diversify its drug pipeline. That deal brought early-stage compounds for age-related macular degeneration. Alexion also purchased an investigational therapy from Orphatec Pharmaceuticals for a rare metabolic disease that affects newborns.
Get stock quote: ALXN
Revenue ($ millions): $589.5
Net Income ($ millions): $102.9
Industry: Health Care
Network with Alexion Pharmaceuticals
From the September 26, 2011 issue.
Revenue and profit figures reflect the four quarters ended on or before April 30,2011.
Total return is through June 30, 2011.

Green Plains Renewable Energy 299%
SXC Health Solutions 151%
Discovery Communications 105%
Sturm Ruger & Co 848%
Cirrus Logic 340%
Hi-Tech Pharmacal 234%
Green Mountain Coffee Roasters 120%
Netflix 116%
Acme Packet 108%
To qualify, a company -- domestic or foreign -- must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market... More